ADMA Biologics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the results of the 2024 Annual Meeting of Stockholders held by ADMA Biologics, Inc. on June 4, 2024. The company is incorporated in Delaware and its common stock trades on the Nasdaq Global Market under the symbol "ADMA".
Key Financial Metrics
This filing is a current report regarding corporate governance events and does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data.
Material Changes
No material financial changes are reported in this document. The filing details the successful completion of two shareholder proposals:
- Election of three Class II directors to serve until the 2027 Annual Meeting.
- Ratification of CohnReznick LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024.
Guidance, Outlook, and Risks
The filing does not provide management guidance, outlook, risk factors, or contingencies. It strictly documents the voting outcomes of the Annual Meeting.
Investor Verification Points
- Shareholder Participation: Of 231,771,523 shares outstanding, 186,655,332 shares were represented at the meeting, establishing a quorum.
- Director Election Results: All three nominees were elected. Young T. Kwon, PhD received the highest "For" vote count (152,744,777), while Steven A. Elms received the lowest (110,136,193) with a significant number of withheld votes (44,858,645).
- Auditor Ratification: The appointment of CohnReznick LLP was ratified with 184,478,528 votes "For" and only 1,983,914 votes "Against".
- Broker Non-Votes: There were 31,660,494 broker non-votes recorded for the director election proposal.